The overall focus of the Project, Molecular Interactions of Lymphoid Cell Receptors, is a broad one, based on the crucial importance of the recognition of MHC molecules by many receptors of the innate and adaptive immune systems. Past collaborations have explored interactions of other receptors such as TLRs (Toll like receptors) and LAIR-1 (the leukocyte-associated inhibitory receptor). Our major interest is focused on MHC molecules and their interactions with T cell receptors, T cell coreceptors, CD8 and CD4, and natural killer (NK) cell receptors. Because of our particular expertise in measurement of interactions of recombinant lymphoid receptors and antibodies using biophysical methods, such as surface plasmon resonance, we often collaborate with colleagues who have other molecules of interest. Thus our work with TLRs and LAIR-1 derives from such collaborative relationships. In the current reporting period, we have collaborated in the examination of the interaction of a set of chimeric antibodies to the bacterial toxin, SEB, demonstrating the relationship between effective neutralization of in vivo toxicity with high affinity. Our general approach is to exploit cloned genes to express recombinant forms of the molecules of interest, to analyze their function using in vitro cellular assays, to analyze their biophysical properties using state-of-the-art methodologies such as surface plasmon resonance and analytical ultracentrifugation, and to understand the three-dimensional structural basis of their function with high-resolution X-ray crystallographic structural models. A major accomplishment of in the past year and a half has been the determination of the X-ray structure of the multimolecular five-subunit complex consisting of MHC/beta-2 microglobulin/peptide/CD8alpha/CD8beta. Although the structure of the first MHC-I molecule was determined in 1987, and the structure of the human CD8 alpha/alpha homodimer was determined in 1992, and structures of CD8 alpha/alpha in complex with MHC-I and of mouse CD8 alpha/beta unliganded have been reported, there has been no successful determination of the structure of the CD8 alpha/beta heterodimer in complex with MHC-I. This is of considerable importance because CD8 alpha/beta, not CD8 alpha/alpha, is the major functional molecule expressed on mature CD8+ cells. Rational strategies to develop highly efficient CTL for killing tumors would depend on knowledge of the MHC/beta2-m/CD8alpha/beta complex. Extensive binding and functional analyses of a battery of CD8 alpha/beta mutants in several laboratories have led to the rather unsatisfying conclusion that CD8 alpha/beta may not bind to MHC-I in a single conformation, but rather may assume one of several different distinct conformations, accounting for several ambiguous results derived from the mutagenesis studies. To address the issue of the nature of the conformation of CD8 alpha/beta when bound to an MHC-I molecule, we explored several different approaches to engineering CD8 alpha/beta for structural studies, and finally succeeded with mouse CD8 alpha and CD8 beta extracellular domains engineered for expression as inclusion bodies in E. coli. These were then solubilized and refolded with minor variations of our standard methods, and stable, disulfide-linked CD8 alpha/beta heterodimers were produced, purified free from contaminating homodimers, and used in co-crystallization trials with bacterially expressed, refolded, highly purified H-2Dd/mouse beta2m/P18-I10 complexes. Crystals were obtained, the best of which diffracted to 2.6 Angstroms. The results of this structure indicate that the CD8beta chain is in the membrane distal position, and reveal numerous details of the interaction of the CD8 heterodimer with the MHC-I molecule. Further efforts in the past year have been devoted to efforts to extend these observations to the human system, where expression of CD8alpha/beta in a form amenable to structural, binding, and functional studies have been difficult.

Project Start
Project End
Budget Start
Budget End
Support Year
19
Fiscal Year
2010
Total Cost
$691,317
Indirect Cost
City
State
Country
Zip Code
Frey, Blake F; Jiang, Jiansheng; Sui, Yongjun et al. (2018) Effects of Cross-Presentation, Antigen Processing, and Peptide Binding in HIV Evasion of T Cell Immunity. J Immunol 200:1853-1864
Margulies, David H (2018) How MHC molecules grab citrullinated peptides to foster rheumatoid arthritis. J Biol Chem 293:3252-3253
Voss, Oliver H; Murakami, Yousuke; Pena, Mirna Y et al. (2016) Lipopolysaccharide-Induced CD300b Receptor Binding to Toll-like Receptor 4 Alters Signaling to Drive Cytokine Responses that Enhance Septic Shock. Immunity 44:1365-78
Murakami, Y; Tian, L; Voss, O H et al. (2014) CD300b regulates the phagocytosis of apoptotic cells via phosphatidylserine recognition. Cell Death Differ 21:1746-57
Subramanian, Naeha; Natarajan, Kannan; Clatworthy, Menna R et al. (2013) The adaptor MAVS promotes NLRP3 mitochondrial localization and inflammasome activation. Cell 153:348-61
Norcross, Michael A; Luo, Shen; Lu, Li et al. (2012) Abacavir induces loading of novel self-peptides into HLA-B*57: 01: an autoimmune model for HLA-associated drug hypersensitivity. AIDS 26:F21-9
Revilleza, Maria Jamela; Wang, Rui; Mans, Janet et al. (2011) How the virus outsmarts the host: function and structure of cytomegalovirus MHC-I-like molecules in the evasion of natural killer cell surveillance. J Biomed Biotechnol 2011:724607
Tilahun, Mulualem E; Kwan, Alan; Natarajan, Kannan et al. (2011) Chimeric anti-staphylococcal enterotoxin B antibodies and lovastatin act synergistically to provide in vivo protection against lethal doses of SEB. PLoS One 6:e27203
Tilahun, Mulualem E; Rajagopalan, Govindarajan; Shah-Mahoney, Nalini et al. (2010) Potent neutralization of staphylococcal enterotoxin B by synergistic action of chimeric antibodies. Infect Immun 78:2801-11
Tang, Xiaobin; Narayanan, Sriram; Peruzzi, Giovanna et al. (2009) A single residue, arginine 65, is critical for the functional interaction of leukocyte-associated inhibitory receptor-1 with collagens. J Immunol 182:5446-52

Showing the most recent 10 out of 13 publications